SS34. Clinical Research Review Anticoagulation for Calf Deep Venous Thrombosis: A Systematic Review and Meta-Analysis  by De Martino, Randall R. et al.
i
p
A
R
i
O
d
N
J
S
C
A
S
R
R
V
L
H
m
L
H
m
s
s
o
a
d
f
S
b
r
a
a
w
t
a
3
q
0
(
s
D
a
a
s
c
p
p
q
JOURNAL OF VASCULAR SURGERY
June Supplement 2011104S AbstractsScore (VCSS) and PTS scoring put forth by Villalta et al
(PTSV), commonly used scoring systems, were used to
appraise PTS at 3, 6, 12, 18 and 24 months following
diagnosis of DVT. Cumulative incidence (CI) served as
the primary outcome measure.
Results:Asmeasured by VCSS, the GCS (study) group
had a cumulative incidence of PTS that was twice that of the
control group. When PTSV was used as the instrument of
measurement, a significant difference in cumulative inci-
dence of PTS in the GCS and control groups was not
found. The break up of incidence at various time intervals is
depicted in table 1.
Conclusions: Use of knee length graduated compres-
sive stockings does not appear to prevent development of
post thrombotic syndrome. When PTS is assessed by the
VCSS instrument the use of stockings seem to contribute to
the incidence of the syndrome.
Table I.
VCSS (Incidence of PTS) PTSV (Incidence of PTS)
Month GCS Group Control Group GCS Group Control Group
3 58% 36% 50% 72%
6 56% 17% 63% 60%
12 59% 15% 59% 46%
18 73% 33% 59% 52%
24 68% 8% 42% 54%
Author Disclosures: A. Jayaraj: Nothing to disclose; M.
Meissner: Jobst - partial funding for study,Research
Grants; C. Natiello: Nothing to disclose; S. Nicholls:
Nothing to disclose.
VS7.
Video Presentation
Resection of Vena Cava for Invasion by Renal Cell
Carcinoma
R Clement Darling, Benjamin B. Chang, Sean P. Roddy,
Manish Mehta, Philip S. Paty, Kathleen J. Ozsvath, Paul B.
Kreienberg, Yaron Sternbach, John B. Taggert, Dhiraj M.
Shah. Vascular Surgery, Albany Medical Center/Albany
Medical College, Albany, NY
Background: Up to 10% of patients with renal cell
carcinoma will have extension into the inferior vena cava. In
those cases, a vascular surgeon is usually asked to assist the
urologist in resection of the vena cava and removal of the
intra caval thrombus.
Technical Description: This video will outline the
operative approach for isolation of the suprahepatic cava
including the hepatic veins, the infrahepatic and infrarenal
vena cava, and the steps involved with removal of the
thrombus bymilking it back through the cava and resection
of the vena cava with non stenotic reconstruction. We have
performed 69 reconstructions with no perioperative
deaths; 80% of these patients required suprahepatic control
and 10% required median stenotomy for extension of the
thrombus into the atrium. The operative technique will be bllustrated and should be valuable for all surgeons who
articipate in this operation.
uthor Disclosures: B. B. Chang: Nothing to disclose;
. Darling: Nothing to disclose; P. B. Kreienberg: Noth-
ng to disclose; M. Mehta: Nothing to disclose; K. J.
zsvath: Nothing to disclose; P. S. Paty: Nothing to
isclose; S. P. Roddy: Nothing to disclose; D. M. Shah:
othing to disclose; Y. Sternbach: Nothing to disclose;
. B. Taggert: Nothing to disclose.
S34.
linical Research Review
nticoagulation for Calf Deep Venous Thrombosis: A
ystematic Review and Meta-Analysis
andall R. De Martino1, Jessica B. Wallaert2, Ana P.
ossi3, Alicia J. Zbehlik4, Daniel B. Walsh1. 1Section of
ascular Surgery, Dartmouth-Hitchcock Medical Center,
ebanon, NH; 2Department of Surgery, Dartmouth-
itchcock Medical Center, Lebanon, NH; 3The Dart-
outh Institute for Health Policy and Clinical Practice,
ebanon, NH; 4Department of Medicine, Dartmouth-
itchcock Medical Center, Lebanon, NH
Objectives: Review evidence for anticoagulation treat-
ent of calf deep venous thrombosis (CDVT).
Methods: Medline, Cochrane Library, meeting ab-
tracts, and expert opinion were reviewed. Criteria for
tudies selected were: (1) Adults with CDVT by ultrasound
r venogram, (2) comparisons of patients treated with
nticoagulation (vitamin K antagonist or heparin) for 30
ays to controls (not anticoagulated), (3)  one month
ollow-up. Primary outcome was pulmonary embolus (PE).
econdary outcomes were clot propagation, post-throm-
otic syndrome, mortality, and bleeding. Two independent
eviewers extracted data from qualifying articles. Quality
ssessment was performed using standardized scales. Meta-
nalyses were performed by generating pooled odds ratios
ith subgroup and sensitivity analyses.
Results: We reviewed 2,328 studies, including 148 full
ext articles. Eight studies met selection criteria (2 RCTs
nd 6 cohort) providing 126 anticoagulated patients and
78 controls. Most studies were of poor methodological
uality and did not report all outcomes. Rates of PE (OR
.12, 95% CI 0.02-0.77, p0.03) and clot propagation
OR 0.29, 95% CI 0.14-0.62, p0.04, Figure 1) were
ignificantly lower in patients treated with anticoagulation.
ue to heterogeneity, results for bleeding complications
nd mortality could not be pooled, but favored controls or
nticoagulation respectively. No data on post-thrombotic
yndrome were available.
Conclusions: Anticoagulation for CDVT may de-
rease clinically important outcomes such as PE and clot
ropagation. Treatment-related complications have been
oorly documented and studies are of poormethodological
uality. More rigorous studies would improve evidenced
ased treatment for calf vein DVT.
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A Prospective Analysis of Endovascular Treatments of
Chronic Cerebrospinal Venous Insufficiency in Pa-
tients with Multiple Sclerosis
Manish Mehta, Sean P. Roddy, R Clement Darling, Ben-
jamin B. Chang, Kathleen J. Ozsvath, Yaron Sternbach,
John B. Taggert, Philip S. Paty, John Byrne, Paul B.
Kreienberg, Dhiraj M. Shah. The Institute for Vascular
Health andDisease, AlbanyMedical College/AlbanyMed-
ical Center Hospital, Albany, NY
Objectives: Recently an association has been made
between Multiple Sclerosis (MS) and Chronic Cere-
brospinal Venous Insufficiency (CCSVI) characterized
by stenosis and reflux of the principal extracranial venous
drainage including the Internal Jugular veins (IJV) and
the Azygous veins (AV). This prospective study evaluates
the safety, feasibility, and efficacy of percutaneous
transluminal angioplasty (PTA) of extracranial venous
stenosis and its influence on the clinical outcomes of MS.
Methods: 100 MS patients underwent a detailed
evaluation of bilateral IJV and AV via selective venogra-
phy, and patients with angiographic evidence of 50%
venous stenosis underwent PTA. Clinical evaluation in-
cluded MS Quality of Life (MSQOL), and Modified
Fatigue Impact Scale (MFIS) at 3, 6, and 12 months.
The study was conducted with IRB approval and statis-
tical analysis was performed using two-tailed Student’s
t-test.
Results: Venography in 100 MS patients identified
178 central veins with 50% stenosis in the IJV
(n160/178, 90%) and AV (n18/178, 10%), ac-
counting for mean 1.8 lesions per patient. In treating IJV
and AV lesions, PTA was technical feasible in 97%,
technical successful in 77% (20% residual stenosis), and
9% of lesions required re-interventions over a mean
follow-up of 4 months. MS patient clinical evaluation
indicated a significant improvement in the mean
MSQOL Physical Health Composite scores (pre-PTA:
40.2 vs. post-PTA: 59.2, p0.002), MSQOL Mental
Health Composite scores (pre-PTA: 52.7 vs. post-PTA:
70.5, p0.006), and Modified Fatigue Impact Scale
Pooled odds ratio of thrombus propagation in anticoagulation and
control patients with calf vein deep venous thrombosis.(pre-PTA: 15.8 vs. post-PTA: 12.2, p0.001). IConclusions: Results of this prospective study sug-
est an association between MS and CCSVI. PTA of
enous stenosis in MS patients with CCSVI is feasible
nd safe, and results in significant clinical improvement
s indicated by MSQOL and MFIS parameters. These
ndings need to be substantiated with future random-
zed blinded controlled trials that evaluate endovascular
nd surgical options for treatment of CCSVI.
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